BOSTON, Dec. 14, 2022 /PRNewswire/ -- Valo Health, Inc ("Valo") shared the initial results of a collaborative study with the U.S. Food and Drug Administration (FDA), demonstrating the potential of ...
Novo Nordisk A/S and Valo Health Inc. have entered into an agreement to discover and develop novel treatments for cardiometabolic diseases. The collaboration will leverage Valo’s Opal Computational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results